东曜药业-B(01875)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01875 东曜药业-B

休市中 09-04 16:08:01

3.795

-0.015

-0.39%

最高3.930	最低3.750	成交量58.52万
今开3.820	昨收3.810	日振幅4.72%
总市值29.34亿	流通市值29.33亿	总股本7.73亿
成交额222.77万	换手率0.08%	流通股本7.73亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01875","market":"HK","secType":"STK","nameCN":"东曜药业-B","latestPrice":3.795,"timestamp":1788509281931,"preClose":3.81,"halted":0,"volume":585200,"delay":0,"changeRate":-0.003937007874015781,"floatShares":772787887,"shares":773000000,"eps":-0.138402,"marketStatus":"休市中","change":-0.015,"latestTime":"09-04 16:08:01","open":3.82,"high":3.93,"low":3.75,"amount":2227670,"amplitude":0.047244,"askPrice":3.825,"askSize":30400,"bidPrice":3.77,"bidSize":800,"shortable":0,"etf":0,"ttmEps":-0.243,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788744600000},"marketStatusCode":7,"adr":0,"listingDate":1573142400000,"exchange":"SEHK","adjPreClose":3.81,"openAndCloseTimeList":[[1788485400000,1788494400000],[1788498000000,1788508800000]],"volumeRatio":1.8439626916297067,"lotSize":400,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01875","defaultTab":"news","newsList":[{"id":"1159308395","title":"东曜药业-B 8月股份变动月报表公布，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1159308395","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159308395?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:58","pubTimestamp":1788512338,"startTime":"0","endTime":"0","summary":"东曜药业股份有限公司于2026年9月4日发布2026年8月股份变动月报表，披露了截至2026年8月31日的股份发行及股本结构最新情况。报告期内，公司法定/注册股本无任何变动。普通股于香港联交所上市的已发行股份总数维持在772,787,887股，库存股份数目为0，整体股本结构保持稳定。公司同时确认已遵守香港联交所《上市规则》及其他适用法律法规。公告由联席公司秘书吕颖一代表董事会签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166143969","title":"东曜药业-B（01875）2026年中期业绩：CDMO收入同比增157% 带动在手订单达3.91亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166143969","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166143969?lang=zh_cn&edition=full","pubTime":"2026-08-21 19:55","pubTimestamp":1787313347,"startTime":"0","endTime":"0","summary":"东曜药业股份有限公司8月21日公布截至2026年6月30日止六个月之未经审核中期业绩。公司期内总收入为人民币2.46亿元，同比下降49.7%。其中，CDMO业务实现收入人民币1.99亿元，同比大幅增长157.0%；自研产品销售收入人民币0.45亿元，同比下降88.6%。受收入结构调整影响，期内整体毛利润人民币0.53亿元，同比下降85.1%；综合毛利率为21.4%。公司在手订单人民币3.91亿元，同比增长95.5%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661606422","title":"东曜药业-B(01875)发布中期业绩 总收入2.46亿元 CDMO业务高速增长 自研产品加速出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2661606422","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661606422?lang=zh_cn&edition=full","pubTime":"2026-08-21 19:55","pubTimestamp":1787313304,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B 发布截至2026年6月30日止六个月中期业绩，2026年上半年，公司合约开发和制造组织项目管线及在手订单快速增长。CMC项目总数由2025年6月30日的98个增至2026年6月30日的134个。2026年上半年，公司总收入为人民币2.46亿元。该下降主要由于自研产品销售收入减少所致，而CDMO业务毛利随该板块业务增长相应提升。2026年上半年，公司持续高效履约，稳步保障全球客户订单交付，CDMO业务实现大幅增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01875","BK1161","BK4139","CDMO","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190386274","title":"东曜药业-B（01875）宣布自2026年8月11日起启用新公司标志","url":"https://stock-news.laohu8.com/highlight/detail?id=1190386274","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190386274?lang=zh_cn&edition=full","pubTime":"2026-08-11 18:20","pubTimestamp":1786443638,"startTime":"0","endTime":"0","summary":"东曜药业-B8月11日在港交所发布公告称，公司已采纳新标志，并自2026年8月11日起生效。公告同时展示了新旧标志以供识别。公司表示，此次标志变更不影响现有股东的任何权利，也不会对公司的业务运营及财务状况造成影响。公司将继续发行载有旧标志的股票，直至库存用完，随后将改用新标志的股票。截至公告日，公司董事会成员包括：执行董事李锦才博士；非执行董事席晓捷先生；独立非执行董事樊欣先生、Ulf Grawunder博士及胡朝红博士。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133676828","title":"东曜药业-B2026年7月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1133676828","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133676828?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:47","pubTimestamp":1785919664,"startTime":"0","endTime":"0","summary":"东曜药业股份有限公司于2026年8月5日公布截至2026年7月31日的证券变动月报表。报告显示，公司上月底及本月底的已发行普通股总数均为772,787,887股，库存股数量保持为零，整体股本结构与上月底相比无变化。根据公告，东曜药业-B当月未发生任何新增股份发行、股份购回或注销等变动；公司已授出的首次公开发售前购股权计划期末结余为20,000份，与上月底持平，本月无行权新增发行或失效情形。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130124462","title":"东曜药业-B：董事会将于8月21日审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1130124462","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130124462?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:11","pubTimestamp":1783674714,"startTime":"0","endTime":"0","summary":"东曜药业股份有限公司（01875，东曜药业-B）7月10日在港交所公告称，公司董事会已定于2026年8月21日（星期五）召开会议，届时将审议并批准本集团截至2026年6月30日止六个月的中期业绩，并处理其他事项。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108651079","title":"东曜药业-B 2026年6月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1108651079","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108651079?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:58","pubTimestamp":1783069107,"startTime":"0","endTime":"0","summary":"东曜药业股份有限公司于2026年7月3日披露2026年6月股份变动月报表，报告期为截至2026年6月30日。公告显示，东曜药业-B上月底已发行普通股为772,787,887股，当月无新增发行或回购注销，公司股本总数仍为772,787,887股，未持有任何库存股份。在股权激励方面，东曜药业-B披露，截至6月末，首发前购股权计划下，共有2万份已授出但未行使的股份期权，报告期内亦无新股因股权激励计划而发行或转让。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646351284","title":"东曜药业-B(01875)：方园获委任为公司联席公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2646351284","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646351284?lang=zh_cn&edition=full","pubTime":"2026-06-26 19:17","pubTimestamp":1782472626,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B(01875)发布公告，公司联席公司秘书陈一帆先生已辞任其职务，自2026年6月26日起生效。方园女士已获委任为公司联席公司秘书，以接替陈先生，自2026年6月26日起生效，但须满足若干条件，包括公司目前另一名联席公司秘书吕颖一先生将自方女士委任生效之日起计获留任3年。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644795877","title":"东曜药业-B(01875)与药明合联(02268)订立工艺开发及制造服务协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2644795877","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644795877?lang=zh_cn&edition=full","pubTime":"2026-06-17 06:30","pubTimestamp":1781649048,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B 及药明合联联合公布，2026年6月16日，东曜药业与药明生物订立工艺开发及制造服务协议，据此，东曜药业将向药明生物提供工艺开发及制造服务。东曜药业须向药明生物交付合共十批符合相关抗体试生产规格的单克隆抗体中间体。公告称，订立工艺开发及制造服务协议有助于东曜药业实现深化其技术诀窍、提升其工艺水平并巩固其交付单克隆抗体及其他生物样品工艺开发服务往绩的目标。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455265.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","02268","BK1161","SG9999014674.SGD","LU2488822045.USD","BK1574","01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151733874","title":"东曜药业-B将向药明生物交付十批单克隆抗体中间体","url":"https://stock-news.laohu8.com/highlight/detail?id=1151733874","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151733874?lang=zh_cn&edition=full","pubTime":"2026-06-17 06:10","pubTimestamp":1781647815,"startTime":"0","endTime":"0","summary":"东曜药业-B已与药明生物达成协议，将分十批次向其供应单克隆抗体药物生产所需的关键中间体。此次交付标志着双方在生物制药领域的合作进一步深化。单克隆抗体中间体是生物药生产链条中的重要环节，此次批量供应将助力药明生物加速相关药物的开发与生产进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148657458","title":"东曜药业-B与药明生物达成工艺开发与生产服务协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1148657458","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148657458?lang=zh_cn&edition=full","pubTime":"2026-06-17 06:09","pubTimestamp":1781647751,"startTime":"0","endTime":"0","summary":"东曜药业-B宣布，已与药明生物签署一项工艺开发与生产服务协议。此举标志着两家生物技术公司在药物开发与商业化生产领域的合作正式展开。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137314931","title":"东曜药业拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1137314931","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137314931?lang=zh_cn&edition=full","pubTime":"2026-06-04 21:52","pubTimestamp":1780581163,"startTime":"0","endTime":"0","summary":"东曜药业-B（01875）公告将寻求股东大会授权，按不超过已发行股份（不包括库存股份）总数的10%进行股份购回。截至最后实际可行日期，公司已发行股份为772,787,887股。若授权获股东批准，公司最高可回购77,278,788股。\n公司透露，拟从其可合法动用的资金中拨付购回款项，具体依据香港适用法律及公司组织章程细则。董事会认为，此举有助于调整资本结构并提高股东回报，符合公司及全体股东的最大利益。\n公告显示，公司计划于2026年6月26日召开股东周年大会，就包括股份购回授权在内的多项决议进行审议并表决。同时，公司将于6月23日至6月26日期间暂停办理股份过户登记手续。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东曜药业拟回购最多10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640163880","title":"东曜药业-B(01875)建议委任德勤为新核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2640163880","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640163880?lang=zh_cn&edition=full","pubTime":"2026-06-04 21:51","pubTimestamp":1780581112,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B(01875)发布公告，罗兵咸永道(罗兵咸永道)将于应届股东周年大会结束后其现任任期届满时退任本公司核数师。董事会根据董事会审计与关联方交易审核委员会的推荐意见，已决议建议委任德勤•关黄陈方会计师行(德勤)为本公司于罗兵咸永道退任后的新核数师(建议委任)，任期直至下届股东周年大会结束为止，惟须待股东于应届股东周年大会上批准，方可作实。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01875","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133274274","title":"东曜药业-B5月无新增发行及股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1133274274","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133274274?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:42","pubTimestamp":1780476171,"startTime":"0","endTime":"0","summary":"东曜药业股份有限公司于2026年6月3日公布了截至2026年5月31日止月份的证券变动月报表。公告显示，公司本月未发生新增股份发行、购回或注销等相关变动事项，股本规模保持稳定。根据公告，东曜药业-B法定及注册股本在本报告期内无变化。普通股方面，截至2026年5月31日，公司已发行股份数量为772,787,887股，期末仍然为772,787,887股，库藏股数量为零。截至5月底，期权总额维持不变，未因此导致新增发行或库藏股变动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640949174","title":"东曜药业(01875)重申基本面稳固 明确未来持续增长路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2640949174","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640949174?lang=zh_cn&edition=full","pubTime":"2026-06-02 22:25","pubTimestamp":1780410304,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东曜药业今日就近期股价出现的不寻常波动发布自愿性公告，向市场及投资者传递积极信号。公告明确表示，公司经营稳健、基本面良好，无任何未披露的重大不利信息，同时披露了与药明合联合并后的整合进展及未来增长路径。在这样的行业背景下，依托药明合联这一全球领先的ADC CDMO平台，东曜药业基本面保持稳固，在手项目储备充足，客户结构持续优化，发展前景正面且可期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449331.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01875","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631562350","title":"港股异动 | 东曜药业-B(01875)盘中涨超9% 药明合联CEO李锦才接任执行董事、董事会主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2631562350","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631562350?lang=zh_cn&edition=full","pubTime":"2026-04-29 15:34","pubTimestamp":1777448085,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东曜药业-B盘中涨超9%，截至发稿，涨6.77%，报4.89港元，成交额1957.1万港元。消息面上，东曜药业公布多位管理层变动。其中，李锦才则获委任为执行董事、董事会主席、提名委员会主席、战略及ESG委员会主席以及薪酬委员会成员，自4月29日起生效。公开资料显示，今年3月，药明合联完成对东曜药业的现金要约收购。国投证券国际指出，东曜药业实现华丽转型，由传统制药企业摇身成为CDMO赛道的领军企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436092.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999014674.SGD","BK4588","BK1574","01875","02268","VXUS","LU2488822045.USD","BK1141","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630585691","title":"东曜药业-B(01875)委任李锦才为执行董事、董事会主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2630585691","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630585691?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:30","pubTimestamp":1777386607,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B(01875)公布，自2026年4月29日起，付山先生已辞任公司执行董事、董事会主席、提名委员会及战略及ESG委员会成员兼主席;刘卫东博士已辞任公司非执行董事、审计与关联方交易审核委员会及战略及ESG委员会成员;孙晖女士已辞任公司独立非执行董事、审计与关联方交易审核委员会成员兼主席及提名委员会成员;张勍先生已辞任公司独立非执行董事、审计与关联方交易审核委员会成员及薪酬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435710.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01875","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164905468","title":"东曜药业-B任命李金才博士为执行董事兼董事会主席","url":"https://stock-news.laohu8.com/highlight/detail?id=1164905468","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164905468?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:29","pubTimestamp":1777386552,"startTime":"0","endTime":"0","summary":"东曜药业-B宣布，正式委任李金才博士担任公司执行董事及董事会主席职务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108511834","title":"东曜药业-B更新3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1108511834","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108511834?lang=zh_cn&edition=full","pubTime":"2026-04-09 17:16","pubTimestamp":1775726197,"startTime":"0","endTime":"0","summary":"东曜药业股份有限公司（股票代码：01875）于2026年4月9日发布截至2026年3月31日的股份变动月报表。公告显示，公司本月法定或注册股本无变化。\n根据公告披露，截至3月31日，公司已发行股份（不含库存股）仍为772,787,887股，与上月持平。报告期内未发生新增发行、回购、注销或库藏股变动。\n在股权激励方面，公司已有的股份期权计划合计7,632,600股期权，本月期间未出现授出、行使或失效，期末结存数量不变。\n公司强调已遵守香港联交所《上市规则》及相关法律规定。该月报表由联席公司秘书吕颖一签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106138065","title":"异动解读 | 药明合联收购要约正式生效，东曜药业-B盘中大涨11.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1106138065","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106138065?lang=zh_cn&edition=full","pubTime":"2026-03-24 14:44","pubTimestamp":1774334696,"startTime":"0","endTime":"0","summary":"东曜药业-B今日盘中股价大幅上涨11.02%，市场表现强劲。消息面上，此次股价异动主要源于药明合联对其发起的现金要约收购已正式生效。据悉，药明合联已取得东曜药业60%股权的有效接纳，标志着此次战略整合进入新阶段。值得注意的是，协同效应已初步显现，药明合联已将部分客户订单转至东曜药业，并获得客户积极反馈，这进一步印证了市场对东曜药业ADC CDMO技术及执行效率的信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01875"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.totbiopharm.com.cn","stockEarnings":[{"period":"1week","weight":-0.0181},{"period":"1month","weight":0.0937},{"period":"3month","weight":0.0426},{"period":"6month","weight":-0.0583},{"period":"1year","weight":0.7488},{"period":"ytd","weight":0.518}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0276},{"period":"6month","weight":-0.0041},{"period":"1year","weight":0.0236},{"period":"ytd","weight":0.0008}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"东曜药业股份有限公司是一家临床阶段生物制药公司，主要从事开发及商业化肿瘤药物及疗法。该公司的主营业务在中华人民共和国从事抗肿瘤药物的研究与开发、生产及营销、合约开发生产组织（CDMO）/合约生产组织（CMOJ）业务以及自主开发生物药物的对外许可。该公司拥有针对各类癌症的在研肿瘤药物管线，当中包括单克隆抗（mAb）及抗体偶联药物（ADC）。该公司已建立起一个集发现、产程开发、质量管理临床前及临床开发以及商业规模的生产基地和销售及营销能力于一体的综合内部平台。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":0.036017},{"month":2,"riseRate":0,"avgChangeRate":-0.037884},{"month":3,"riseRate":0.571429,"avgChangeRate":0.015652},{"month":4,"riseRate":0.714286,"avgChangeRate":0.047512},{"month":5,"riseRate":0.571429,"avgChangeRate":0.050736},{"month":6,"riseRate":0.571429,"avgChangeRate":-0.030847},{"month":7,"riseRate":0.285714,"avgChangeRate":0.017209},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.017448},{"month":9,"riseRate":0.571429,"avgChangeRate":0.008608},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.041625},{"month":11,"riseRate":0,"avgChangeRate":-0.064081},{"month":12,"riseRate":0.714286,"avgChangeRate":0.042078}],"exchange":"SEHK","name":"东曜药业-B","nameEN":"BIODLINK-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东曜药业-B(01875)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东曜药业-B(01875)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东曜药业-B,01875,东曜药业-B股票,东曜药业-B股票老虎,东曜药业-B股票老虎国际,东曜药业-B行情,东曜药业-B股票行情,东曜药业-B股价,东曜药业-B股市,东曜药业-B股票价格,东曜药业-B股票交易,东曜药业-B股票购买,东曜药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东曜药业-B(01875)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东曜药业-B(01875)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}